We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rockland Immunochemicals and LDI Form Antibody Commercialization Partnership
News

Rockland Immunochemicals and LDI Form Antibody Commercialization Partnership

Rockland Immunochemicals and LDI Form Antibody Commercialization Partnership
News

Rockland Immunochemicals and LDI Form Antibody Commercialization Partnership

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Rockland Immunochemicals and LDI Form Antibody Commercialization Partnership"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Rockland Immunochemicals Inc. has announced a new licensing venture with LIMR Development, Inc. (LDI), the business development subsidiary of the Lankenau Institute for Medical Research (LIMR).

Rockland Immunochemicals will market LDI’s entire portfolio of LIMR monoclonal and polyclonal antibodies, which bind biomarkers crucial for cell signaling, immune system regulation, inflammatory responses, cellular metabolism, and cancer progression.

Detailed product information can be found at http://rockland-inc.com/limr-collaboration.aspx.

George Prendergast, PhD, President and CEO of LIMR, stated, “We are proud of the achievement of LDI to generate an agreement with Rockland to commercialize the high-quality research antibodies developed at LIMR.”

"LIMR's work in cancer and inflammation is an elegant fit with Rockland's antibody portfolio and technology platform. We partner with leading institutions to bring to researchers the reagents vital to the advance of their key research. The Philadelphia region is home to some of the world's finest research centers. We are proud to bring the unique scientific and commercial opportunities of the LIMR/LDI/Rockland collaboration to the global research community," commented James Fendrick, President and CEO of Rockland Immunochemicals.

Advertisement